References
- The ALSUntangled Group. ALSUntangled No 23: the rife machine and retroviruses. Amyotroph Lateral Scler and Frontotemporal Degen. 2014;15:157–9.
- URL: http://www.alsuntangled.com/open.php. 2018. Archived by WebCite® at http://www.webcitation.org/6y4ZtZEfe. Accessed March 20, 2018.
- Lyons J, Venna N, Cho T. Atypical nervous system manifestations of HIV. Semin Neurol. 2011;31:254–65.
- Farhadian S, Patel P, Spudich S. Neurological complications of HIV infection. Curr Infect Dis Rep. 2017;19:50.
- Alfahad T, Nath A. Retroviruses and amyotrophic lateral sclerosis. Antiviral Res. 2013;99:180–7.
- Bowen LN, Tyagi R, Li W, Alfahad T, Smith B, Wright M, et al. HIV-associated motor neuron disease: HERV-K activation and response to antiretroviral therapy. Neurology. 2016;87:1756–62.
- Küry P, Nath A, Créange A, Dolei A, Marche P, Gold J, et al. Human endogenous retroviruses in neurological diseases. Trends Mol Med. 2018;24:379–94.
- Araujo A, Silva M. The HTLV-1 neurological complex. Lancet Neurol. 2006;5:1068–76.
- Oh U, Jacobson S. Treatment of HTLV-I-associated myelopathy/tropical spastic paraparesis: towards rational targeted therapy. Neurol Clin. 2008;26:781–97.
- Steele AJ, Al-Chalabi A, Ferrante K, Cudkowicz ME, Brown RH, Garson JA. Detection of serum reverse transcriptase activity in patients with ALS and unaffected blood relatives. Neurology. 2005;64:454–8.
- Li W, Lee MH, Henderson L, Tyagi R, Bachani M, Steiner J, et al. Human endogenous retrovirus-K contributes to motor neuron disease. Sci Transl Med. 2015;7:307ra153.
- Arru G, Mameli G, Deiana GA, Rassu AL, Piredda R, et al. Humoral immunity response to HERV-K/W differentiates between amyotrophic lateral sclerosis and other neurological diseases. Eur J Neurol. 2018. [Epub ahead of print].
- Hovden H, Frederiksen JL, Pedersen SW. Immune system alterations in amyotrophic lateral sclerosis. Acta Neurol Scand. 2013;128:287–96.
- Sako W, Ito H, Yoshida M, Koizumi H, Kamada M, Fujita K, et al. Nuclear factor-κB expression in patients with sporadic amyotrophic lateral sclerosis and hereditary amyotrophic lateral sclerosis with optineurin mutations. Nature. 2012;31:418–23.
- Manghera M, Ferguson-Parry J, Lin R, Douville RN. NF-κB and IRF1 induce endogenous retrovirus K expression via interferon-stimulated response elements in its 5′ long terminal repeat. J Virol. 2016;90:9338–49.
- Manghera M, Ferguson J, Douville RN. ERVK polyprotein processing and reverse transcriptase expression in human cell line models of neurological disease. Viruses. 2015;7:320–32.
- Gao FB, Almeida S, Lopez-Gonzalez R. Dysregulated molecular pathways in amyotrophic lateral sclerosis–frontotemporal dementia spectrum disorder. Embo J. 2017;36:2931–50.
- Steinacker P, Hendrich C, Sperfeld A, Jesse S, von Arnim C, Lehnert S, et al. TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol. 2008;65:1481–7.
- Kasai T, Tokuda T, Ishigami N, Sasayama H, Foulds P, Mitchell DJ, et al. Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol. 2009;117:55–62.
- Noto YI, Shibuya K, Sato Y, Kanai K, Misawa S, Sawai S, et al. Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis: specificity, sensitivity, and a possible prognostic value. ALS. 2011;12:140–3.
- Hosokawa M, Arai T, Yamashita M, Tsuji H, Nonaka T, Masuda-Suzukake M, et al. Differential diagnosis of amyotrophic lateral sclerosis from Guillain–Barre syndrome by quantitative determination of TDP-43 in cerebrospinal fluid. Intl J Neurosci. 2014;124:344–9.
- Bourbouli M, Rentzos M, Bougea A, Zouvelou V, Constantinides V, Zaganas I, et al. Cerebrospinal fluid TAR DNA-binding protein 43 combined with tau proteins as a candidate biomarker for amyotrophic lateral sclerosis and frontotemporal dementia spectrum disorders. Dement Geriatr Cogn Disord. 2017;44:144–52.
- Verstraete E, Kuiperij H, van Blitterswijk M, Veldink J, Schelhass H, van den Berg LH, et al. TDP-43 plasma levels are higher in amyotrophic lateral sclerosis. Amyotrophic Lateral Scler. 2012;13:446–51.
- Manghera M, Ferguson-Parry J, Douville RN. TDP-43 regulates endogenous retrovirus-K viral protein accumulation. Neurobiol Dis. 2016;94:226–36.
- Krug L, Chatterjee N, Borges-Monroy R, Hearn S, Liao WW, Morrill K, et al. Retrotransposon activation contributes to neurodegeneration in a Drosophila TDP-43 model of ALS. PLoS Genet. 2017;13:e1006635.
- Li W, Jin Y, Prazak L, Hammell M, Dubnau J. Transposable elements in TDP-43-mediated neurodegenerative disorders. PLoS One. 2012;7:e44099.
- Douville RN, Nath A. Human endogenous Retrovirus-K and TDP-43 expression bridges ALS and HIV neuropathology. Front Microbiol. 2017;8:1986.
- Douville RN, Nath A. Human endogenous retroviruses and the nervous system. Handb Clin Neurol. 2014;123:465–85.
- Christensen T. Human endogenous retroviruses in neurologic disease. APMIS. 2016;124:116–26.
- Kassiotis G, Stoye J. Making a virtue of necessity: the pleiotropic role of human endogenous retroviruses in cancer. Phil Trans R Soc B. 2017;372:20160277.
- Meyer T, Rosenkrantz J, Carbone L, Chavez SL. Endogenous retroviruses: with us and against Us. Front Chem. 2017;5:23.
- Christensen T. Human endogenous retroviruses in the aetiology of MS. Acta Neurol Scand. 2017;136:18–21.
- Arneth B. Up-to-date knowledge about the association between multiple sclerosis and the reactivation of human endogenous retrovirus infections. J Neurol. 2018. [Epub ahead of print]. doi: 10.1007/s00415-018-8783-1.
- Bhat RK, Rudnick W, Antony JM, Maingat F, Ellestad KK, Wheatley BM, et al. Human endogenous Retrovirus-K(II) envelope induction protects neurons during HIV/AIDS. PLoS One. 2014;9:e97984.
- Wildschutte JH, Williams ZH, Montesion M, Subramanian RP, Kidd JM, Coffin JM. Discovery of unfixed endogenous retrovirus insertions in diverse human populations. Proc Natl Acad Sci USA. 2016;113:E2326–34.
- Turner G, Barbulescu M, Su M, Jensen-Seaman MI, Kidd KK, Lenz J. Insertional polymorphisms of full-length endogenous retroviruses in humans. Curr Biol. 2011;11:1531–5.
- Contreras-Galindo R, Kaplan MH, Dube D, Gonzalez-Hernandez MJ, Chan S, Robinson D, et al. Human endogenous retrovirus type K (HERV-K) particles package and transmit HERV-K-related sequences. J Virol. 2015;89:7187–201.
- Tyagi R, Li W, Parades D, Bianchet M, Nath A. Inhibition of human endogenous retrovirus-K by antiretroviral drugs. Retrovirology. 2017;14:21.
- Contreras-Galindo R, Dube D, Fujinaga K, Kaplan M, Markovitz D. Susceptibility of human endogenous retrovirus type K to reverse transcriptase inhibitors. J Virol. 2017;91:e01309-17.
- Towler E, Gulnik S, Bhat T, Xie D, Gustschina E, Sumpter TR, et al. Functional characterization of the protease of human endogenous retrovirus, K10: can it complement HIV-1 protease? Biochemistry. 1998;37:17137–44.
- Kuhelj R, Rizzo C, Chang CH, Jadhav P, Towler E, Korant B. Inhibition of human endogenous retrovirus-K10 protease in cell-free and cell-based assays. J Biol Chem. 2001;276:16674–82.
- Hansen DT, Petersen T, Christensen T. Retroviral envelope proteins: involvement in neuropathogenesis. J Neurol Sci. 2017;380:151–63.
- Zhang K, Rana F, Silva C, Ethier J, Wehrly K, Chesebro B, et al. HIV-1 envelope-mediated neuronal death: uncoupling of viral replication and neurotoxicity. J Virol. 2003;77:6899–912.
- URL: https://www.businesswire.com/news/home/20170-207006054/en/GeNeuro-Signs-CRADA-Agreement-NIH-Develop-Antibody. 2018. Archived by WebCite® at http://www.webcitation.org/6ySLSFqQL. Accessed April 5, 2018.
- Margolis DM, Garcia JV. Countering HIV three's the charm? N Engl J Med. 2018;378:295–7.
- Casci I, Pandey U. A fruitful endeavor: modeling ALS in the fruit fly. Brain Res. 2015;1607:47–74.
- URL: https://www.patientslikeme.com/conditions/9-amyotrophic-lateral-sclerosis. 2018. Accessed February 14, 2018.
- Westarp M, Bartmann P, Rossler J, Geiger E, Westphal KP, Schreiber H, et al. Antiretroviral therapy in sporadic adult amyotrophic lateral sclerosis. NeuroReport. 1992;4:819–22.
- Calcagno A, Di Perri G, Bonora S. Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system. Clin Pharmacokinet. 2014;53:891–906.
- Sclesa SN, MacGowan D, Mitsumoto H, Imperato T, LeValley AJ, Liu MH, et al. A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS. Neurology. 2005;64:1298–300.
- URL: https://clinicaltrials.gov/ct2/show/NCT02868580. 2018. Archived by WebCite® at http://www.webcitation.org/6xFy1ti0a. Accessed February 15, 2018.
- URL: https://clinicaltrials.gov/ct2/show/NCT02437110. 2018. Archived by WebCite® at http://www.webcitation.org/6xFy4Hrfu. Accessed February 15, 2018.
- Retrovir [package insert]. Research Triangle Park, NC: ViiV Healthcare Group; 2014.
- URL: https://www.patientslikeme.com/treatments/show/1832. 2018. Archived by WebCite® at http://www.webcitation.org/6y8cmnLNb. Accessed March 23, 2018.
- Crixivan [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; 2016.
- URL: https://www.patientslikeme.com/treatments/show/1854. 2018. Archived by WebCite® at http://www.webcitation.org/6y8eJd1Nl. Accessed March 23, 2018.
- Triumeq [package insert]. Research Triangle Park, NC: ViiV Healthcare Group; 2017.
- Genvoya [package insert]. Foster City, CA: Gilead Sciences; 2017.
- URL: https://www.patientslikeme.com/treatments/show/27225. 2018. Archived by WebCite® at http://www.webcitation.org/6y8eWDsvS. Accessed March 23, 2018.
- URL: https://www.patientslikeme.com/treatments/show/27955. 2018. Archived by WebCite® at http://www.webcitation.org/6y8echqn6. Accessed March 23, 2018.
- URL: https://www.goodrx.com/triumeq?drug-name=triumeq. 2018. Archived by WebCite® at http://www.webcitation.org/6y4ZKBVd1. Accessed March 20, 2018.
- URL: https://www.goodrx.com/genvoya?drug-name=genvoya. 2018. Archived by WebCite® at http://www.webcitation.org/6y4Z1QTGE. Accessed March 20, 2018.